Xenon (XENE) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xenon Pharmaceuticals is set to present new long-term data on azetukalner, a promising treatment for focal onset seizures, at the American Epilepsy Society Annual Meeting. This includes insights into the mental health and comorbidity burdens associated with the condition. Additionally, Xenon will share developments from its Nav1.1 program, highlighting its innovative research approach.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.